Tango Therapeutics, Inc. (NASDAQ:TNGX) Position Boosted by Nebula Research & Development LLC

Nebula Research & Development LLC raised its position in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) by 376.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 51,924 shares of the company’s stock after buying an additional 41,023 shares during the quarter. Nebula Research & Development LLC’s holdings in Tango Therapeutics were worth $160,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of TNGX. Gilead Sciences Inc. acquired a new stake in Tango Therapeutics during the fourth quarter worth about $15,000,000. Blue Owl Capital Holdings LP bought a new position in shares of Tango Therapeutics during the fourth quarter valued at approximately $5,352,000. Schroder Investment Management Group acquired a new stake in shares of Tango Therapeutics during the 4th quarter worth approximately $2,031,000. Dimensional Fund Advisors LP boosted its position in Tango Therapeutics by 83.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 662,776 shares of the company’s stock valued at $2,048,000 after purchasing an additional 302,087 shares during the period. Finally, TRV GP VI LLC bought a new position in Tango Therapeutics during the 4th quarter worth $600,000. Institutional investors own 78.99% of the company’s stock.

Insider Activity

In other Tango Therapeutics news, CEO Barbara Weber sold 9,778 shares of the company’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total value of $29,236.22. Following the completion of the sale, the chief executive officer now directly owns 1,631,264 shares in the company, valued at $4,877,479.36. This represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 24,268 shares of company stock worth $72,561 over the last three months. Corporate insiders own 6.30% of the company’s stock.

Tango Therapeutics Price Performance

Shares of Tango Therapeutics stock opened at $1.51 on Friday. Tango Therapeutics, Inc. has a 1-year low of $1.11 and a 1-year high of $12.02. The business’s fifty day moving average price is $1.60 and its two-hundred day moving average price is $2.91. The company has a market capitalization of $163.24 million, a P/E ratio of -1.28 and a beta of 1.03.

Tango Therapeutics (NASDAQ:TNGX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The company had revenue of $4.12 million during the quarter, compared to analyst estimates of $7.84 million. Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. On average, research analysts expect that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Tango Therapeutics in a research note on Monday, April 14th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $12.33.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.